title: Mantle Cell Lymphoma: A North Indian Tertiary Care Centre
  Experience
abstract: Background: Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin’s lymphoma, with a pathognomonic
  chromosomal translocation t (11;14). Prognosis is uniformly dismal but there is a paucity of information on MCL from
  India. Materials and methods: We retrospectively analysed clinicopathological information on all treated patients with
  MCL at our centre. STATA 14.0 was used for analysis. Survival was assessed by Kaplan-Meier analysis and the Cox’s
  proportional hazards method. Statistical significance was defined as a P value of < 0.05. Results: Fifty-one patients with
  MCL were reviewed. The median age at presentation was 57.0 years. Extranodal involvement was seen in 39.0 (74.0%)
  while bone marrow positivity at presentation was found in 27.0 (54.0%). Initial treatment was chemotherapy with or
  without rituximab. Patients receiving rituximab-based therapy (n = 24) had 5-year progression-free survival (PFS) of 21.0
  (88.0%), compared with 14.0 (61.0%) for those not receiving rituximab (n = 23, P = 0.036). Twenty-three patients were
  alive with a median follow-up of 20.7 months (range 2.5-89.2). PFS at 1 and 2 years was 51.0% and 27.0%, and overall
  survival (OS) 78.0% and 72.0%, respectively. Use of more than 2.0 lines of therapy, use of bendamustine-rituximab,
  and high TLC (>10,000.0/cu.mm) significantly affected PFS. Conclusions: In our experience, MCL patients from
  north India have an early age at presentation. When treated with regimens including rituximab results in an improved
  response rate and PFS. This study provided comprehensive insights into the treatment of MCL in a developing country.
authors.affiliation: Department of Medical Oncology, IRCH, All India Institute of Medical Science, New Delhi, India. Email: ajaygogia@gmail.com.
authors.forename: Chandan Krushna
authors.initials: ChK
authors.lastname: Das
authors.forename: Ajay
authors.initials: A
authors.lastname: Gogia
authors.forename: Lalit
authors.initials: L
authors.lastname: Kumar
authors.forename: Atul
authors.initials: A
authors.lastname: Sharma
authors.forename: Mehar Chand
authors.initials: MCh
authors.lastname: Sharma
authors.forename: Saumya Ranjan
authors.initials: SR
authors.lastname: Mallick
keywords: Chemotherapy; mantle-cell lymphoma; non-Hodgkin’s lymphoma; bendamustine